MO2-5 Impact of pre-treatment AXL expression on EGFR-TKI efficacy in EGFR-mutated non-small cell lung cancer patients

EGFR-tyrosine kinase inhibitors (TKIs) have marked efficacy in patients with EGFR-mutated non-small cell lung cancer (NSCLC). However, some patients show intrinsic resistance and an insufficient response to EGFR-TKIs. We previously reported the crucial role of the AXL pathway in the intrinsic resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. However, the relationship between AXL expression in tumors and the therapeutic efficacy of EGFR-TKIs...